drugset

drugset / Trial / NCT02118077

Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer

NCT02118077 ↗

Phase 3 Completed 154 enrolled Cancer Advances Inc.

RandomizedQuadruple-blindTreatment

Summary

Compare the effect of G17DT with that of placebo on the survival of subjects with advanced pancreatic cancer.

Timeline

Start: 2001-04
Primary completion: 2004-04
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	G17DT Immunogen	Vaccine	250 ug	Intramuscular

Indications